Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria… - Nature reviews …, 2015 - nature.com
High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths,
and overall survival has not changed significantly for several decades. In this Opinion article …
and overall survival has not changed significantly for several decades. In this Opinion article …
The biological and therapeutic relevance of mRNA translation in cancer
SP Blagden, AE Willis - Nature reviews Clinical oncology, 2011 - nature.com
Protein synthesis is a tightly regulated process that enables post-transcriptional control of
gene expression. Dysregulation of this process is associated with the development and …
gene expression. Dysregulation of this process is associated with the development and …
[HTML][HTML] The La-related proteins, a family with connections to cancer
C Stavraka, S Blagden - Biomolecules, 2015 - mdpi.com
The evolutionarily-conserved La-related protein (LARP) family currently comprises Genuine
La, LARP1, LARP1b, LARP4, LARP4b, LARP6 and LARP7. Emerging evidence suggests …
La, LARP1, LARP1b, LARP4, LARP4b, LARP6 and LARP7. Emerging evidence suggests …
[HTML][HTML] Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free …
AR Clamp, EC James, IA McNeish, A Dean, JW Kim… - The Lancet, 2019 - thelancet.com
Background Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-
line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a …
line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a …
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs
RM Lahr, BD Fonseca, GE Ciotti, HA Al-Ashtal, JJ Jia… - Elife, 2017 - elifesciences.org
The 5'terminal oligopyrimidine (5'TOP) motif is a cis-regulatory RNA element located
immediately downstream of the 7-methylguanosine [m7G] cap of TOP mRNAs, which …
immediately downstream of the 7-methylguanosine [m7G] cap of TOP mRNAs, which …
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies
D Olmos, D Barker, R Sharma, AT Brunetto, TA Yap… - Clinical cancer …, 2011 - AACR
Purpose: GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1). A phase I
study of two schedules of intravenous GSK461364 was conducted. Experimental Design …
study of two schedules of intravenous GSK461364 was conducted. Experimental Design …
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in …
M Slusarczyk, MH Lopez, J Balzarini… - Journal of medicinal …, 2014 - ACS Publications
Gemcitabine is a nucleoside analogue commonly used in cancer therapy but with limited
efficacy due to a high susceptibility to cancer cell resistance. The addition of a …
efficacy due to a high susceptibility to cancer cell resistance. The addition of a …
The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration
C Burrows, N Abd Latip, SJ Lam… - Nucleic acids …, 2010 - academic.oup.com
The RNA binding protein Larp1 was originally shown to be involved in spermatogenesis,
embryogenesis and cell-cycle progression in Drosophila. Our data show that mammalian …
embryogenesis and cell-cycle progression in Drosophila. Our data show that mammalian …
The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer
TG Hopkins, M Mura, HA Al-Ashtal… - Nucleic acids …, 2016 - academic.oup.com
RNA-binding proteins (RBPs) are increasingly identified as post-transcriptional drivers of
cancer progression. The RBP LARP1 is an mRNA stability regulator, and elevated …
cancer progression. The RBP LARP1 is an mRNA stability regulator, and elevated …
A study of symptoms described by ovarian cancer survivors
C Stavraka, A Ford, S Ghaem-Maghami, T Crook… - Gynecologic …, 2012 - Elsevier
OBJECTIVE: A cross-sectional, observational study to evaluate physical and psychological
symptoms experienced by patients following completion of treatment for ovarian cancer and …
symptoms experienced by patients following completion of treatment for ovarian cancer and …